Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia.
OBJECTIVE
To evaluate the treatment of endometrial hyperplasia (EH) with different progestins.


METHODS
Eighty-two women with simple EH without atypia were included. Patients were offered oral progestagens and were randomized to one of three options for 3 months: medroxyprogesterone acetate (MPA, 10 mg/day), lynestrenol (LYN, 15 mg/day) and norethisterone (NET, 15 mg/day) for 10 days per cycle. Patients were reevaluated after treatment. Women diagnosed with proliferative and nonatypical EH at the second curettage were offered the same progestins for another 3 months. The primary outcome of the study was the proportion of women requiring further treatment.


RESULTS
Of the 82 women, 46 (56.1%) received MPA (23.2%), LYN (13.4%) and NET (19.5%) therapy for another 3 months at the end of the first 3 months of treatment. The patients receiving MPA showed resolution in 36.7% of the cases versus 37% in the NET group. The highest resolution rate (56%) was observed in the LYN group, although there was no statistically significant difference between progestins regarding the proportion of women requiring further treatment (χ(2) = 2.608; p = 0.271).


CONCLUSIONS
It seems that the efficacies of oral progestins are similar at these dosages in simple EH without atypia.
Gynecology Clinic, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey. ozlemerman@gmail.com
Ozlem
O
Ozdegirmenci
Fulya
F
Kayikcioglu
Ulku
U
Bozkurt
Mehmet Akif
MA
Akgul
Ali
A
Haberal
D000328:Adult; D004714:Endometrial Hyperplasia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000008:administration & dosage; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage; D011372:Progestins / Q000008:administration & dosage*; D011446:Prospective Studies; D016896:Treatment Outcome
D011372:Progestins; D017258:Medroxyprogesterone Acetate; D008234:Lynestrenol; D009640:Norethindrone